Even if that's true at high enough oral doses (the evidence is mixed), it's a fundamentally different mechanism from a prescription GLP-1 medicine
[1] [4] Semaglutide activates the same GLP-1 receptors as the endogenous hormone, producing comparable physiological effects but with sustained duration
If side effects are already interfering with eating or hydration, increasing the dose may make the problem worse
Some researchers discover that their side effects improve equally with time on standard dosing, making microdosing unnecessary
Meanwhile, Novo Nordisk and Eli Lilly surged into the ranks of the worlds most valuable companies, pipelines swelling with oral formulations, dual and triple agonists, and weight-loss hybrids that fold in amylin and other pathways
Finally, there are mechanisms of action of these GLP-1s that we don't completely understand.